Usted buscó: oropharyngeal (Danés - Inglés)

oropharyngeal epilepsi
oropharyngeal epilepsy

kliniske succesrater i oropharyngeal candidiasis
clinical success rates in oropharyngeal candidiasis

kliniske succesrater i oropharyngeal candidiasis endpoint
clinical success rates in oropharyngeal candidiasis endpoint

munden på grund af risiko for oropharyngeal ulceration.
sucked or allowed to dissolve in the mouth on account of the risk of oropharyngeal ulceration.

behandling af azol-følsom oropharyngeal candidiasis (opc)
treatment of azole-susceptible oropharyngeal candidiasis (opc)

se produktresuméet for noxafil oral suspension for oplysninger om brug til oropharyngeal candidiasis.
please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.

patienten må ikke tygge eller sutte tabletterne på grund af risiko for oropharyngeal ulceration.
patients should not chew or suck the tablet, because of a potential for oropharyngeal ulceration.

patienten må ikke tygge eller sutte på tabletterne på grund af risiko for oropharyngeal ulceration.
patients should not chew or suck the tablet, because of a potential for oropharyngeal ulceration.

• patienterne må ikke tygge eller sutte på tabletterne på grund af risiko for oropharyngeal ulceration
- patients should not chew or suck the tablet because of a potential for oropharyngeal ulceration.

tabletterne må ikke tygges, suges eller opløses i munden på grund af risiko for oropharyngeal ulceration.
the tablets should not be chewed, sucked or allowed to dissolve in the mouth on account of the risk of oropharyngeal ulceration.

- oropharyngeal candidiasis: som first- line behandling hos patienter, der har alvorlig sygdom eller
- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are

femoral arterieindstikssted cabg- relateret genital/ urinal gastrointestinal retroperitoneal oral/ oropharyngeal hæmoglobin/ hæmatokrit reduktion
femoral artery access cabg-related genitourinary gastrointestinal retroperitoneal oral/ oropharyngeal haemoglobin/ haematocrit decrease

oropharyngeal candidiasis: som first-line behandling hos patienter, der har alvorlig sygdom eller har nedsat immunforsvar, hos hvem respons på lokal behandling forventes at være dårlig.
oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.

posaconazole sp anvendes desuden til behandling af patienter med "trøske" (oropharyngeal candidiasis), som er en svampeinfektion i munden og svælget forårsaget af candida.
posaconazole sp is also used to treat patients with oropharyngeal candidiasis or ‘thrush’, a fungal infection of the mouth and throat due to candida.

15 almindelig:abdominalsmerter, dyspepsi, obstipation, diarré, flatu -mave-tarmkanalen: lens, esophageal ulcus *, dysphagi *, abdominal udspiling, syreregurgitation.ikke almindelig:kvalme, opkastning, gastritis, esophagitis *, esopha -geal erosion *, melaena.sjælden:esophagusstriktur *, oropharyngeal ulceration *, øvre gastrointestinale pubs (perforation, ulcera, blødning) (se pkt.4. 4) . * se pkt.4. 2 og 4. 4.ikke almindelig:udslæt, kløe, erythema.hud og subkutane sjælden:udslæt med lysoverfølsomhed. væv:meget sjælden:
common: abdominal pain, dyspepsia, constipation, diarrhoea, gastrointestinal flatulence, oesophageal ulcer*, dysphagia*, abdominal distension, disorders: acid regurgitation uncommon: nausea, vomiting, gastritis, oesophagitis*, oesophageal erosions*, melena rare: oesophageal stricture*, oropharyngeal ulceration*, upper gastrointestinal pubs (perforation, ulcers, bleeding)(see section 4.4) . *see sections 4.2 and 4.4 uncommon: rash, pruritus, erythema skin and rare: rash with photosensitivity subcutaneous tissue very rare: severe skin reactions including stevens-johnson syndrome disorders: and toxic epidermal necrolysis common: musculoskeletal (bone, muscle or joint) pain musculoskeletal and rare: severe musculoskeletal (bone, muscle or joint) pain (see connective tissue section 4.4) disorders: